Tarenflurbil
PubChem CID
92337
Primary Hazards
Molecular Formula
Synonyms
- Tarenflurbil
- 51543-40-9
- (R)-Flurbiprofen
- Flurizan
- R-Flurbiprofen
Molecular Weight
244.26 g/mol
Computed by PubChem 2.2 (PubChem release 2025.09.15)
Dates
- Create:2005-06-08
- Modify:2026-04-04
Description
(R)-flurbiprofen is a flurbiprofen. It is an enantiomer of a (S)-flurbiprofen.
Tarenflurbil is an investigational drug that was studied in patients with mild Alzheimer's disease. It is a selective amyloid lowering agent (SALA) that reduces levels of the toxic peptide amyloid beta 42 (Aβ42) in cultured human cells and in animal models. Aβ42 is the primary initiator of neurotoxicity and amyloid plaque development in the brains of Alzheimer's disease patients. In June 2008 development of the drug for Alzheimer's disease was discontinued. Tarenflurbil has also been used in trials studying the treatment of Prostate Cancer.
Tarenflurbil is an orally active synthetic enantiomer of flurbiprofen. Tarenflurbil activates c-Jun N terminal kinase, increases AP-1 binding to DNA, and downregulates cyclin D1 expression, resulting in arrest of tumor cells in the G1 phase of the cell cycle and apoptosis. This agent also affects the expression of nuclear factor kappa B, a rapid response transcription factor that stimulates the immune response to tumor cells. R-flurbiprofen does not inhibit the enzyme cyclo-oxygenase.
Chemical Structure Depiction
Interactive Chemical Structure Model
Conformer of 10
(2R)-2-(3-fluoro-4-phenylphenyl)propanoic acid
Computed by Lexichem TK 2.9.3 (PubChem release 2025.09.15)
InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)/t10-/m1/s1
Computed by InChI 1.07.4 (PubChem release 2025.09.15)
SYTBZMRGLBWNTM-SNVBAGLBSA-N
Computed by InChI 1.07.4 (PubChem release 2025.09.15)
C[C@H](C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O
Computed by OEChem 4.2.0 (PubChem release 2025.09.15)
C15H13FO2
Computed by PubChem 2.2 (PubChem release 2025.09.15)
TARENFLURBIL
MeSH Entry Terms for tarenflurbil
tarenflurbil
MeSH Entry Terms for flurizan
flurizan
MeSH Entry Terms for MPC-7869
- MPC-7869
- MPC7869
MeSH Entry Terms for E-7869
E-7869
- Tarenflurbil
- 51543-40-9
- (R)-Flurbiprofen
- Flurizan
- R-Flurbiprofen
- MPC-7869
- (2R)-2-(3-fluoro-4-phenylphenyl)propanoic acid
- (-)-Flurbiprofen
- Flurbiprofen, (r)-
- Tarenflurbilo
- (-)-(2R)-2-(2-fluorobiphenyl-4-yl)propanoic acid
- (R)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid
- (2R)-2-(2-fluorobiphenyl-4-yl)propanoic acid
- E-7869
- 501W00OOWA
- CHEBI:38666
- DTXSID40199508
- MPC7869
- NSC685699
- (2R)-2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid
- tarenflurbilum
- (2R)-2-(2-fluoro-(1,1'-biphenyl-4-yl))propanoic acid
- RefChem:891169
- TMP001
- DTXCID30121999
- E7869
- E 7869
- 257-264-7
- (R)-2-Flurbiprofen
- (R)-2-(2-Fluoro-[1,1'-biphenyl]-4-yl)propanoic acid
- (2r)-2-(3-Fluoro-4-Phenyl-Phenyl)propanoic Acid
- MFCD00869714
- CHEMBL190083
- (R)-()-2-Fluoro-alpha-methyl-4-biphenylacetic acid
- Stayban
- Adfeed
- (R)-2-Flubiprofen
- Furbiprofen
- SFPP
- Flurbiprofen (Ansaid)
- Tarenflurbil [USAN]
- R-(-)-Flurbiprofen
- (R)-(-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid
- (R)-Flurbiprofen;MPC7869
- Tarenflurbil [USAN:INN]
- UNII-501W00OOWA
- Flurbirprofen
- TruNoc
- R-form
- (R)-2-(3-Fluoro-4-phenylphenyl)propanoic acid
- NCGC00016654-01
- FLP
- CAS-5104-49-4
- EINECS 257-264-7
- 2-Fluoro-alpha-methyl-4-biphenylacetic acid
- flurbiprofen-(+/-)
- Tocris-1769
- TARENFLURBIL [MI]
- Tarenflurbil (USAN/INN)
- TARENFLURBIL [INN]
- SCHEMBL26131
- GTPL7340
- orb1689861
- SCHEMBL29350102
- MSK8083
- HMS3649K13
- BDBM50172473
- MSK8083-100A
- AKOS015891228
- CS-6056
- DB05289
- NSC-685699
- NCGC00016654-03
- NCGC00018157-01
- NCGC00018157-02
- NCGC00018157-06
- NCGC00018157-07
- NCGC00025287-01
- [1, 2-fluoro-.alpha.-methyl-, (R)-
- AS-44113
- HY-10291
- NS00068141
- (R)-2-(2-fluorobiphenyl-4-yl)propionic acid
- D09010
- (r)-2-(2-fluoro-biphenyl-4-yl)-propionic acid
- AB01274714-01
- AB01274714_02
- Q849769
- SR-01000946580
- (R)-()-2-Fluoro-|A-methyl-4-biphenylacetic acid
- (R)-(-)-2-Fluoro-a-methyl-4-biphenylacetic acid
- SR-01000946580-1
- (R)-Flurbiprofen Solution in Acetonitrile, 100ug/mL
- (2R)-2-(2-Fluoro-1,1'-biphenyl-4-yl)propanoic acid
- (2R)-2-(2-Fluoro[1,1'-biphenyl]-4-yl)propanoic acid
- (R)-2-(2-Fluoro-[1,1'-biphenyl]-4-yl)propanoicacid
- (2R)-2-(2-fluoro-[1,1''-biphenyl-4-yl])propanoic acid
- (R)-2-fluoro-alpha-methyl(1,1''-biphenyl)-4-acetic acid
- (R)-(-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid, 97%
- (1,1'-Biphenyl)-4-acetic acid, 2-fluoro-alpha-methyl-, (alphaR)-
Property Name
Property Value
Reference
Property Name
Molecular Weight
Property Value
244.26 g/mol
Reference
Computed by PubChem 2.2 (PubChem release 2025.09.15)
Property Name
XLogP3
Property Value
4.2
Reference
Computed by XLogP3 3.0 (PubChem release 2025.09.15)
Property Name
Hydrogen Bond Donor Count
Property Value
1
Reference
Computed by Cactvs 3.4.8.24 (PubChem release 2025.09.15)
Property Name
Hydrogen Bond Acceptor Count
Property Value
3
Reference
Computed by Cactvs 3.4.8.24 (PubChem release 2025.09.15)
Property Name
Rotatable Bond Count
Property Value
3
Reference
Computed by Cactvs 3.4.8.24 (PubChem release 2025.09.15)
Property Name
Exact Mass
Property Value
244.08995782 Da
Reference
Computed by PubChem 2.2 (PubChem release 2025.09.15)
Property Name
Monoisotopic Mass
Property Value
244.08995782 Da
Reference
Computed by PubChem 2.2 (PubChem release 2025.09.15)
Property Name
Topological Polar Surface Area
Property Value
37.3 Ų
Reference
Computed by Cactvs 3.4.8.24 (PubChem release 2025.09.15)
Property Name
Heavy Atom Count
Property Value
18
Reference
Computed by PubChem
Property Name
Formal Charge
Property Value
0
Reference
Computed by PubChem
Property Name
Complexity
Property Value
286
Reference
Computed by Cactvs 3.4.8.24 (PubChem release 2025.09.15)
Property Name
Isotope Atom Count
Property Value
0
Reference
Computed by PubChem
Property Name
Defined Atom Stereocenter Count
Property Value
1
Reference
Computed by PubChem
Property Name
Undefined Atom Stereocenter Count
Property Value
0
Reference
Computed by PubChem
Property Name
Defined Bond Stereocenter Count
Property Value
0
Reference
Computed by PubChem
Property Name
Undefined Bond Stereocenter Count
Property Value
0
Reference
Computed by PubChem
Property Name
Covalently-Bonded Unit Count
Property Value
1
Reference
Computed by PubChem
Property Name
Compound Is Canonicalized
Property Value
Yes
Reference
Computed by PubChem (release 2025.09.15)
Biphenyls
Pharmaceuticals -> Listed in ZINC15
S55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | DOI:10.5281/zenodo.3247749
MoNA ID
MS Category
Experimental
MS Type
LC-MS
MS Level
MS2
Precursor Type
[M+H]+
Precursor m/z
245.097
Instrument
qTof
Ionization Mode
positive
Top 5 Peaks
199.090988 100
178.075974 57.16
179.084442 30.64
184.065948 23.25
183.060608 16.01
Follow these links to do a live 2D search or do a live 3D search for this compound, sorted by annotation score. This section is deprecated (see the neighbor discontinuation help page for details), but these live search links provide equivalent functionality to the table that was previously shown here.
Same Connectivity Count
Same Stereo Count
Same Isotope Count
Same Parent, Connectivity Count
Same Parent, Stereo Count
Same Parent, Isotope Count
Same Parent, Exact Count
Mixtures, Components, and Neutralized Forms Count
Similar Compounds (2D)
Similar Conformers (3D)
Propionic Acid (annotation moved to)
Flurbiprofen (annotation moved to)
Provider
Information
CATO Research Chemicals Inc. (Chemical Vendors, Research and Development)
PubChem SID: 513775003
Purchasable Chemical: C4X-144430
PubChem SID: 521252955
Purchasable Chemical: API51543409
PubChem SID: 521252956
Purchasable Chemical: API51543409-1
PubChem SID: 522870398
Purchasable Chemical: RM-F210646
PubChem SID: 434700898
Purchasable Chemical: CSSB00016999465
PubChem SID: 518804172
Purchasable Chemical: MSK8083-100A
PubChem SID: 485280332
Purchasable Chemical: TRC-F598730
PubChem SID: 496034419
Purchasable Chemical: TRC-F598730-1G
PubChem SID: 496034421
Purchasable Chemical: TRC-F598730-250MG
PubChem SID: 491982842
Purchasable Chemical: MCULE-3439710050
PubChem SID: 492840180
Purchasable Chemical: MCULE-4717843338
PubChem SID: 254761129
Purchasable Chemical: 51543-40-9
PubChem SID: 91699354
Purchasable Chemical: MolPort-003-936-370
PubChem SID: 523956452
Purchasable Chemical: 51543-40-9
PubChem SID: 470634392
Purchasable Chemical: CQ_51543-40-9
PubChem SID: 464560861
Purchasable Chemical: starbld0819013
PubChem SID: 438650704
Purchasable Chemical: ACM51543409
PubChem SID: 152030647
Purchasable Chemical: AKOS015891228
PubChem SID: 506207541
Purchasable Chemical: CAS-51543-40-9
PubChem SID: 516449655
Purchasable Chemical: orb1689861
PubChem SID: 251916067
Purchasable Chemical: 51543-40-9
PubChem SID: 24878847
Purchasable Chemical: 545740_ALDRICH
MeSH Heading
EFO Term
Max Phase
Investigated for use/treatment in alzheimer's disease and prostate cancer.
- TMP001 in Relapsing-remitting Multiple SclerosisCTID: NCT02686788Phase: Phase 2Status: CompletedDate: 2018-11-21
- Bioavailability, Pharmacokinetics and Tissue Distribution of R-flurbiprofen Capsules in Healthy SubjectsCTID: NCT02206854Phase: Phase 1Status: CompletedDate: 2015-09-11
- R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of RecurrenceCTID: NCT00045123Phase: Phase 2Status: Unknown statusDate: 2013-12-18
- Efficacy Study of MPC-7869 to Treat Patients With Alzheimer'sCTID: NCT00105547Phase: Phase 3Status: CompletedDate: 2009-05-05
- Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer'sCTID: NCT00322036Phase: Phase 3Status: TerminatedDate: 2008-08-05
Page of 2
- TMP001 in relapsing-remitting multiple sclerosis: a multicentre open, baseline-controlled phase IIa clinical trialEudraCT: 2014-004483-38Phase: Phase 2Status: CompletedDate: 2015-07-16
- Phase IIa, multi-center, randomized, double-blind, vehicle-controlled study for assessment of clinical skin condition and effects on barrier impairment of a topical formulation containing tarenflurbil on lesional skin in subjects with mild to moderate atopic eczemaEudraCT: 2011-002571-42Phase: Phase 2Status: CompletedDate: 2011-11-29
- Open Label Study of the Effect of Daily Treatment with MPC-7869 in Subjects withEudraCT: 2007-003362-17Phase: Phase 3Status: Completed, Prematurely Ended, OngoingDate: 2008-01-04
- Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer's TypeEudraCT: 2006-000654-43Phase: Phase 3Status: Completed, Prematurely EndedDate: 2006-07-31
Max Phase
Phase 3
Structure
Gene
Protein
Open Targets Target ID
Mechanism of Action
Structure
Gene
Protein
Open Targets Target ID
Mechanism of Action
Gamma-secretase modulator
Structure
Gene
Protein
Open Targets Target ID
Mechanism of Action
Gamma-secretase modulator
Structure
Gene
Protein
Open Targets Target ID
Mechanism of Action
Gamma-secretase modulator
Structure
Gene
Protein
Open Targets Target ID
Mechanism of Action
Gamma-secretase modulator
Structure
Gene
Protein
Open Targets Target ID
Mechanism of Action
Gamma-secretase modulator
Page of 2
Analgesics
Compounds capable of relieving pain without the loss of CONSCIOUSNESS.
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
Gamma Secretase Inhibitors and Modulators
Agents that suppress GAMMA-SECRETASE by inhibiting or modulating its activities. Targeted enzymatic activities include its involvement in accumulation of toxic AMYLOID BETA-PEPTIDES (e.g., Aβ42) in ALZHEIMER DISEASE and activation of NOTCH RECEPTOR mediated SIGNAL PATHWAYS in certain cancer types.
Cyclooxygenase Inhibitors
Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.
Flurbiprofen has known human metabolites that include (2S,3S,4S,5R)-6-[(2R)-2-(3-fluoro-4-phenylphenyl)propanoyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
MPC-7869 is not an inhibitor of cyclooxygenase enzymes (COX-1 and COX-2). The compound modulates the signal transduction and transcription activation pathways associated with nuclear factor kappaB (NFkappaB), a principle transcription factor in the expression of many molecules involved in cell growth, cell death and inflammation. In addition, MPC-7869 has recently been shown to modulate gamma-secretase and selectively lower levels of Abeta42 peptide in vitro and in vivo, and to reduce amyloid pathology in the brain. MPC-7869 has an excellent safety profile and is very potent in animal models of cancer and Alzheimer's disease. In transgenic mouse studies, MPC-7869 reduced brain amyloid levels and prevented memory loss.
Predecessor
Predecessor Name
Successor
Successor Name
Transformation
Enzyme
Evidence DOI
Predecessor
Predecessor Name
Successor
Successor Name
Transformation
O-glucuronidation / Human Phase II
Enzyme
Evidence DOI
Pictogram(s)
Signal
Danger
GHS Hazard Statements
H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]
ECHA C&L Notifications Summary
Aggregated GHS information provided per 68 reports by companies from 3 notifications to the ECHA C&L Inventory.
Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
Acute Tox. 3 (100%)
- Publication Name: Molecular CancerPublication Date: 2025-07-24
- Publication Name: Molecular NeurodegenerationPublication Date: 2025-06-16
- Publication Name: Cellular and Molecular NeurobiologyPublication Date: 2025-04-18
- Publication Name: Reactions WeeklyPublication Date: 2025-03-15
- Publication Name: Drugs & AgingPublication Date: 2025-02-20
Page of 91
- Publication Date: 2023Publication Name: Nasal Drug Delivery
- Publication Date: 2025Publication Name: Screen, Diagnose, Manage and Monitor
- Publication Date: 2025Publication Name: Biomaterials and Neurodegenerative Disorders
- Publication Date: 2023Publication Name: Nasal Drug Delivery
Page of 59
- Publication Date: 2025Publication Name: Indian Seed Sector
- Publication Date: 2022Publication Name: Journal of Leather Science and Engineering
- Publication Date: 2002Publication Name: Prostate Cancer: New Horizons in Research and Treatment
- Publication Date: 2005Publication Name: Cancer Chemoprevention
Page of 9
- Publication Date: 2022Publication Name: Synfacts
- Publication Date: 2019Publication Name: Synfacts
- Publication Date: 2013Publication Name: Synfacts
Chemical
Selected evidence
Chemical
Selected evidence
182 articles
View All- [Perioperative anesthetic management of a patient with multiple sclerosis]PMID 19522276; Masui. The Japanese journal of anesthesiology 2009-06-01
- Preparation and Characterization of Poly(D,L-Lactic-Co-Glycolic Acid) Microspheres Containing Flurbiprofen SodiumPMID 16423798; DOI 10.1080/10717540500313331; Drug Delivery 2006-01-01
- RETRACTED: Influence of age on flurbiprofen axetil requirements for preventing pain on injection of propofol in japanese adult surgical patients: A prospective, randomized, double-blind, vehicle-controlled, parallel-group, dose-ranging studyPMID 16982288; DOI 10.1016/j.clinthera.2006.08.015; Clinical Therapeutics 2006-08-01
Chemical
Selected evidence
84 articles
View All- Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathologyPMID 22892055; DOI 10.1186/1750-1326-7-39; Molecular Neurodegeneration 2012-08-14
- Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicityPMID 16542055; DOI 10.2165/00126839-200607020-00003; Drugs in R & D 2006-03-01 (Review Article)
- [Gamma-secretase inhibitors and modulators]PMID 22755160; Nihon rinsho. Japanese journal of clinical medicine 2011-12-01 (Review Article)
Chemical
Selected evidence
100 articles
View All- Sensitive and Stereospecific High-Performance Liquid Chromatographic Method for Flurbiprofen in Human PlasmaPMID 35023091; DOI 10.1007/978-3-030-78787-5_9; Advances in experimental medicine and biology 2021-01-01
- Tarenflurbil Protection from Cytotoxicity is Associated with an Upregulation of NeurotrophinsPMID 18997293; DOI 10.3233/jad-2008-15306; Journal of Alzheimer's disease : JAD 2008-10-24
- Evaluating the enantiospecific differences of non-steroidal anti-inflammatory drugs (NSAIDs) using an ecotoxicity bioassay test batteryPMID 31386950; DOI 10.1016/j.scitotenv.2019.133659; The Science of the total environment 2019-12-01
Gene/Protein/Enzyme
Selected evidence
Gene/Protein/Enzyme
Selected evidence
10 articles
View All- (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2PMID 22053353; DOI 10.1038/nchembio.663; Nature Chemical Biology 2011-09-25
- A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitroPMID 17447067; DOI 10.1007/s00280-007-0462-3; Cancer Chemotherapy and Pharmacology 2007-04-20
- Substrate-Selective Inhibition of Cyclooxygenase-2: Development and Evaluation of Achiral Profen ProbesPMID 22984634; DOI 10.1021/ml3001616; ACS Medicinal Chemistry Letters 2012-08-15
Gene/Protein/Enzyme
Selected evidence
7 articles
View All- Structural Analysis of NSAID Binding by Prostaglandin H2 Synthase: Time-Dependent and Time-Independent Inhibitors Elicit Identical Enzyme ConformationsPMID 11318639; DOI 10.1021/bi010045s; Biochemistry 2001-04-04
- The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agentPMID 16455248; DOI 10.1016/j.bmcl.2006.01.033; Bioorganic & Medicinal Chemistry Letters 2006-04-15
- Design, synthesis, and biological evaluation of a novel class of gamma-secretase modulators with PPARgamma activityPMID 20503989; DOI 10.1021/jm1003073; Journal of Medicinal Chemistry 2010-05-26
Gene/Protein/Enzyme
Selected evidence
3 articles
View All- Drug development for Alzheimer's disease: Where are we now and where are we headed?PMID 19616185; DOI 10.1016/j.amjopharm.2009.06.003; The American Journal of Geriatric Pharmacotherapy 2009-06-01 (Review Article)
- The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agentPMID 16455248; DOI 10.1016/j.bmcl.2006.01.033; Bioorganic & Medicinal Chemistry Letters 2006-04-15
- Synthesis and Biological Activity of Flurbiprofen Analogues as Selective Inhibitors of β-Amyloid1-42SecretionPMID 16134939; DOI 10.1021/jm0502541; Journal of Medicinal Chemistry 2005-08-06
Disease
Selected evidence
Disease
Selected evidence
10 articles
View All- Presenilin-dependent regulated intramembrane proteolysis and gamma-secretase activityPMID 19189053; DOI 10.1007/s00018-009-8435-9; Cellular and molecular life sciences : CMLS 2009-02-04 (Review Article)
- Staging anti-inflammatory therapy in Alzheimer’s diseasePMID 21152343; DOI 10.3389/fnagi.2010.00142; Frontiers in Aging Neuroscience 2010-01-01
- Statins and therapy of Alzheimer's disease: questions of efficacy versus trial designPMID 22264400; DOI 10.1186/alzrt101; Alzheimer's Research & Therapy 2012-01-16
Disease
Selected evidence
3 articles
View All- Staging anti-inflammatory therapy in Alzheimer’s diseasePMID 21152343; DOI 10.3389/fnagi.2010.00142; Frontiers in Aging Neuroscience 2010-01-01
- Statins and therapy of Alzheimer's disease: questions of efficacy versus trial designPMID 22264400; DOI 10.1186/alzrt101; Alzheimer's Research & Therapy 2012-01-16
- Amyloid-modifying therapies for Alzheimer’s disease: therapeutic progress and its implicationsPMID 20640545; DOI 10.1007/s11357-010-9142-z; Age (Dordrecht, Netherlands) 2010-04-20 (Review Article)
Disease
Selected evidence
1 article
View All- Corneal Cross-Linking for the Treatment of Keratoconus in a Patient with Ipsilateral Myelinated Retinal Nerve Fiber LayerPMID 21475609; DOI 10.1159/000326486; Case Reports in Ophthalmology 2011-03-08
Organism
Selected evidence
Organism
Selected evidence
20 articles
View All- Drug development for Alzheimer's disease: Where are we now and where are we headed?PMID 19616185; DOI 10.1016/j.amjopharm.2009.06.003; The American Journal of Geriatric Pharmacotherapy 2009-06-01 (Review Article)
- Structural Analysis of NSAID Binding by Prostaglandin H2 Synthase: Time-Dependent and Time-Independent Inhibitors Elicit Identical Enzyme ConformationsPMID 11318639; DOI 10.1021/bi010045s; Biochemistry 2001-04-04
- Prediction of the Effects of Genetic Polymorphism on the Pharmacokinetics of CYP2C9 Substrates from In Vitro DataPMID 19082874; DOI 10.1007/s11095-008-9781-2; Pharmaceutical Research 2008-12-12
Organism
Selected evidence
3 articles
View All- Structural Analysis of NSAID Binding by Prostaglandin H2 Synthase: Time-Dependent and Time-Independent Inhibitors Elicit Identical Enzyme ConformationsPMID 11318639; DOI 10.1021/bi010045s; Biochemistry 2001-04-04
- SAR-studies of γ-secretase modulators with PPARγ-agonistic and 5-lipoxygenase-inhibitory activity for Alzheimer’s diseasePMID 25575659; DOI 10.1016/j.bmcl.2014.12.073; Bioorganic & Medicinal Chemistry Letters 2015-02-15
- Design, synthesis, and biological evaluation of a novel class of gamma-secretase modulators with PPARgamma activityPMID 20503989; DOI 10.1021/jm1003073; Journal of Medicinal Chemistry 2010-05-26
Organism
Selected evidence
7 articles
View All- Notch Antagonists: Potential Modulators of Cancer and Inflammatory DiseasesPMID 27045975; DOI 10.1021/acs.jmedchem.5b01516; Journal of Medicinal Chemistry 2016-04-18 (Review Article)
- Discovery of 4-aminomethylphenylacetic acids as γ-secretase modulators via a scaffold design approachPMID 22061640; DOI 10.1016/j.bmcl.2011.10.047; Bioorganic & Medicinal Chemistry Letters 2011-12-15
- SAR-studies of γ-secretase modulators with PPARγ-agonistic and 5-lipoxygenase-inhibitory activity for Alzheimer’s diseasePMID 25575659; DOI 10.1016/j.bmcl.2014.12.073; Bioorganic & Medicinal Chemistry Letters 2015-02-15
- Publication Number: CN-120284921-APriority Date: 2025-05-06
- Publication Number: CN-120037177-APriority Date: 2025-04-10
- Publication Number: CN-120463591-APriority Date: 2025-04-01
- Publication Number: CN-120022235-APriority Date: 2025-02-25
- Publication Number: CN-119707663-APriority Date: 2025-02-11
Page of 2,924
Patents are available for this chemical structure:
https://patentscope.wipo.int/search/en/result.jsf?inchikey=SYTBZMRGLBWNTM-SNVBAGLBSA-N
Chemical
Selected evidence
Chemical
Selected evidence
57 patents from 43 patent families
View All- Medicament and its production and use in the treatment of pain, inflammation and fever in man and animalsUS-5200198-A; Grant Date: 1993-04-06
- Flurbiprofen-containing immediate-effect medicament and its useUS-5556638-A; Grant Date: 1996-09-17
- Slow-release flurbiprofen-containing medicament and its useEP-0615447-B1; Grant Date: 1996-03-06
Chemical
Selected evidence
469 patents from 368 patent families
View All- Process for the production of amorphous atorvastatin calciumUS-6528660-B1; Grant Date: 2003-03-04
- Optically active isonicotinate anilide derivative and plant growth regulator composition comprising the sameJP-2739762-B2; Grant Date: 1998-04-15
- Method for purifying optically active α-methyl-bis-3,5- (trifluoromethyl) benzylaminesJP-3902384-B2; Grant Date: 2007-04-04
Chemical
Selected evidence
47 patents from 43 patent families
View All- Optically active compound and method for producing the sameJP-2578658-B2; Grant Date: 1997-02-05
- Process for producing optically active compound having pyridine skeletonJP-2691986-B2; Grant Date: 1997-12-17
- Production method of optically active compoundJP-2838527-B2; Grant Date: 1998-12-16
Disease
Selected evidence
Disease
Selected evidence
169 patents from 114 patent families
View All- Ophthalmic antiinflammatory compositions comprising S(+)-flurbiprofenUS-4996209-A; Grant Date: 1991-02-26
- Medicament and its production and use in the treatment of pain, inflammation and fever in man and animalsUS-5200198-A; Grant Date: 1993-04-06
- Improved anti-inflammatory combinations having reduced ulcerogenicityEP-0017169-B1; Grant Date: 1983-03-09
Disease
Selected evidence
53 patents from 33 patent families
View All- Medicament and its production and use in the treatment of pain, inflammation and fever in man and animalsUS-5200198-A; Grant Date: 1993-04-06
- Sustained/enhanced antipyretic responseUS-5286751-A; Grant Date: 1994-02-15
- Improved anti-inflammatory combinations having reduced ulcerogenicityEP-0017169-B1; Grant Date: 1983-03-09
Disease
Selected evidence
28 patents from 19 patent families
View All- Use of r-arylpropionic acids for producing medicaments for treating illnesses with a rheumatic natureEP-1322305-B1; Grant Date: 2005-12-07
- Medicament and its production and use in the treatment of pain, inflammation and fever in man and animalsUS-5200198-A; Grant Date: 1993-04-06
- Flurbiprofen-containing immediate-effect medicament and its useUS-5556638-A; Grant Date: 1996-09-17
Gene
Selected evidence
Gene
Selected evidence
133 patents from 104 patent families
View All- Methods of making high enantioselective secondary alcoholsUS-11773118-B2; Grant Date: 2023-10-03
- Production method of optically active compoundJP-3555480-B2; Grant Date: 2004-08-18
- Method for producing high purity optically active alcoholJP-3606618-B2; Grant Date: 2005-01-05
Gene
Selected evidence
28 patents from 23 patent families
View All- Production method of optically active compoundJP-2838527-B2; Grant Date: 1998-12-16
- Method for producing high purity optically active alcoholJP-3606618-B2; Grant Date: 2005-01-05
- Semi-continuous process for the production of optically active alcohols.JP-3606620-B2; Grant Date: 2005-01-05
Gene
Selected evidence
6 patents from 5 patent families
View All- Microorganisms having multiple genes encoding PHA synthase, and methods for producing PHA using themJP-6994057-B2; Grant Date: 2022-01-14
- A microorganism having a gene encoding a PHA synthase, and a method for producing PHA using the microorganism.JP-6860489-B2; Grant Date: 2021-04-14
- Method for producing 1,4-butanediol and microorganismJP-6243851-B2; Grant Date: 2017-12-06
Organism
Selected evidence
Organism
Selected evidence
101 patents from 83 patent families
View All- Process for producing optically active compound having pyridine skeletonJP-2691986-B2; Grant Date: 1997-12-17
- Production method of optically active compoundJP-2707076-B2; Grant Date: 1998-01-28
- Production method of optically active compoundJP-2838527-B2; Grant Date: 1998-12-16
Organism
Selected evidence
36 patents from 28 patent families
View All- Optically active compound and method for producing the sameJP-2578658-B2; Grant Date: 1997-02-05
- Preparation of optically active 4-halogeno-1,3-butanediol and its derivatives by microorganismsJP-3705046-B2; Grant Date: 2005-10-12
- Production of R-form 1,2-propanediol by microbial culture methodJP-3758566-B2; Grant Date: 2006-03-22
Organism
Selected evidence
241 patents from 161 patent families
View All- Sustained/enhanced analgesiaUS-4927854-A; Grant Date: 1990-05-22
- Sustained/enhanced antipyretic responseUS-5286751-A; Grant Date: 1994-02-15
- Smooth muscle spasmolytic agents, compositions and methods of use thereofUS-6207852-B1; Grant Date: 2001-03-27
- X-ray structure of high-strength hydrogel-grown FABP3 crystal soaked in 50% DMSO solution containing FlurbiprofenPDB Code: 7EUVResolution: 1.280000 Å
Protein
Gene
Taxonomy
Action
Evidence
Data Source
Protein
Gene
Taxonomy
Action
Evidence
Data Source
Protein
Gene
Taxonomy
Action
Modulator
Evidence
Data Source
Protein
Gene
Taxonomy
Action
Modulator
Evidence
Data Source
Protein
Gene
Taxonomy
Action
Evidence
Data Source
Protein
Gene
Taxonomy
Action
Inhibitor
Evidence
Data Source
Page of 5
Page of 87
- An orally active synthetic enantiomer of flurbiprofen. Tarenflurbil activates c-Jun N terminal kinase, increases AP-1 binding to DNA, and downregulates cyclin D1 expression, resulting in arrest of tumor cells in the G1 phase of the cell cycle and apoptosis. This agent also affects the expression of nuclear factor kappa B, a rapid response transcription factor that stimulates the immune response to tumor cells. R-flurbiprofen does not inhibit the enzyme cyclo-oxygenase.
- CTDComparative Toxicogenomics Database - CTD selects and organizes gene, sequence, chemical, reference, and taxonomic data about gene-chemical interactions. It is hosted at North Carolina State University (NCSU).
- ChEBIChemical Entities of Biological Interest - Dictionary of molecular entities focused on "small" chemical compounds. ChEBI is part of the EMBL-European Bioinformatics Institute.
- ClinicalTrials.govClinicalTrials.gov - ClinicalTrials.gov offers up-to-date information for locating federally and privately supported clinical trials for a wide range of diseases and conditions
- DSLDomestic Substance List of Canada - The DSL list is an inventory of substances manufactured in, imported into or used in Canada on a commercial scale
- DrugPortalDrug Information Portal - Portal to selected drug information from the U.S. National Library of Medicine and other key U.S. Government agencies
Page of 4
- EnzymeBiological molecules that possess catalytic activity. They may occur naturally or be synthetically created. Enzymes are usually proteins, however CATALYTIC RNA and CATALYTIC DNA molecules have also been identified. [MESH:D004798]
- OxidoreductaseThe class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9) [MESH:D010088]
- Membrane receptorCell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. [MESH:D011956]
- Aspartic protease A22A regulatory subfamily
- CXC chemokine receptorChemokine receptors that are specific for CXC CHEMOKINES. [MESH:D054387]
Page of 2
- H301: Toxic if swallowed [Danger: Acute toxicity, oral]
- Acute toxicity, oral
GHS06
- P264: Wash hands [and ...] thoroughly after handling.
- P270: Do not eat, drink or smoke when using this product.
Page of 2
- A 2017 list of REACH chemicals including InChIKeys and spectral information, provided by N. Alygizakis and J. Slobodnik, EI. Dataset DOI:10.5281/zenodo.2653020
- HBM4EU CECscreen is a suspect screening list for Chemicals of Emerging Concern (CECs) plus metadata and predicted Phase 1 metabolites; this list contains the CECs only. CECScreen is part of the HBM4EU project (coord. UBA) > WP16 emerging chemicals (lead INRA, JP Antignac/L Debrauwer) > Task 16.1 (lead IRAS, J Vlanderen / R Vermeulen) > Main contributor (J Meijer) > Involved Partners (M Lamoree, T Hamers, S Hutinet, A, Covaci, C Huber, M Krauss, DI Walker, EL Schymanski). Further details in Meijer et al (2021) DOI:10.1016/j.envint.2021.106511. Dataset DOI:10.5281/zenodo.3956586
- List of chemicals on the market from the Swedish Chemicals Agency (KEMI). Provided by Stellan Fischer, KEMI including Hazard and Exposure scores. Curated by Reza Aalizadeh, University of Athens. Dataset DOI:10.5281/zenodo.2628786
- The Metabolite Reaction Database, MetXBioDB, is a biotransformation database used to improve the knowledge- and machine learning-based systems of BioTransformer (http://biotransformer.ca/) by Djoumbou-Feunang et al (2019), DOI:10.1186/s13321-018-0324-5. Dataset DOI:10.5281/zenodo.4056560
- A merged list of >100,000 structures from the NORMAN Network Suspect List Exchange, available from https://www.norman-network.com/nds/susdat/. Compiled by Reza Aalizadeh, University of Athens, including RTI and toxicity values, support by Nikiforos Alygizakis, EI. Hazard and Exposure values provided by Stellan Fischer, KEMI. Dataset DOI:10.5281/zenodo.2664077
- Short_Description: The domestic substances list (DSL) is the sole standard against which a substance is judged to be "new" to Canada.
- Short_Description: HBM4EU CECscreen is a suspect screening list for Chemicals of Emerging Concern (CECs) plus metadata and predicted Phase 1 metabolites
- Short_Description: COMPARA: A list related to the publication (in review), the "Collaborative Modeling Project for Androgen Receptor Activity (CoMPARA)" which follows on from the Collaborative Estrogen Receptor Activity Prediction Project (CERAPP)
- Short_Description: CPDat Structure lists are versioned iteratively and this panel navigates between the various versions
- Short_Description: The Metabolite Reaction Database, MetXBioDB, is a biotransformation database underpinning the BioTransformer application.
Page of 4
- Exact mass range 1-250Cases where the chemical structure exact mass is in the range of 1-250 Daltons
- This node contains the Organofluorine Compound content from the ChEBI Ontology, which defines an organofluorine compound as a compound containing at least one carbon-fluorine bond
- chiral compoundsCompounds that cannot be superposed on its mirror image by any combination of rotations, translations, and some conformational changes.
- monocarboxylic acids
- biphenyls
- drug like compoundsUsing a Fragment Based Druglikeness from OpenChemLib > -1
- benzenes
Page of 4
- A progressive, neurodegenerative disease characterized by loss of function and death of nerve cells in several areas of the brain leading to loss of cognitive function such as memory and language.
- A loss of global cognitive ability of sufficient amount to interfere with normal social or occupational function. Dementia represents a loss of previously present cognitive abilities, generally in adults, and can affect memory, thinking, language, judgment, and behavior.
- A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.
- CAS Common ChemistryLICENSEThe data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc/4.0/(-)-Flurbiprofenhttps://commonchemistry.cas.org/detail?cas_rn=51543-40-9
- ChemIDplusTarenflurbil [USAN:INN]https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0051543409ChemIDplus Chemical Information Classificationhttps://pubchem.ncbi.nlm.nih.gov/source/chemidplus
- DrugBankLICENSECreative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)https://www.drugbank.ca/legal/terms_of_useTarenflurbilhttps://www.drugbank.ca/drugs/DB05289
- EPA DSSToxTarenflurbilhttps://comptox.epa.gov/dashboard/DTXSID40199508CompTox Chemicals Dashboard Chemical Listshttps://comptox.epa.gov/dashboard/chemical-lists/
- European Chemicals Agency (ECHA)LICENSEUse of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.https://echa.europa.eu/web/guest/legal-notice(R)-2-fluoro-α-methyl[1,1'-biphenyl]-4-acetic acidhttps://chem.echa.europa.eu/100.052.041(R)-2-fluoro-α-methyl[1,1'-biphenyl]-4-acetic acid (EC: 257-264-7)https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/92990
- FDA Global Substance Registration System (GSRS)LICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- ChEBI(R)-flurbiprofenhttps://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:38666ChEBI Ontologyhttps://www.ebi.ac.uk/chebi/
- NCI Thesaurus (NCIt)LICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuseNCI Thesaurushttps://ncit.nci.nih.gov
- ChEMBLLICENSEAccess to the web interface of ChEMBL is made under the EBI's Terms of Use (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/).http://www.ebi.ac.uk/Information/termsofuse.htmlChEMBL Protein Target Treehttps://www.ebi.ac.uk/chembl/g/#browse/targets
- Open TargetsLICENSEDatasets generated by the Open Targets Platform are freely available for download.https://platform-docs.opentargets.org/licenceDisease Classificationhttps://www.opentargets.org/
- ClinicalTrials.govLICENSEThe ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use.https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
- Drug Gene Interaction database (DGIdb)LICENSEThe data used in DGIdb is all open access and where possible made available as raw data dumps in the downloads section.http://www.dgidb.org/downloadsTARENFLURBILhttps://www.dgidb.org/drugs/ncit:C26666
- Therapeutic Target Database (TTD)R-flurbiprofenhttps://ttd.idrblab.cn/data/drug/details/D05FGR
- DTP/NCILICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuse
- EU Clinical Trials Register
- Japan Chemical Substance Dictionary (Nikkaji)
- KEGGLICENSEAcademic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial licensehttps://www.kegg.jp/kegg/legal.htmlTarget-based classification of drugshttp://www.genome.jp/kegg-bin/get_htext?br08310.keg
- MassBank of North America (MoNA)LICENSEThe content of the MoNA database is licensed under CC BY 4.0.https://mona.fiehnlab.ucdavis.edu/documentation/license
- Metabolomics Workbench
- NIAID ChemDBLICENSEThe NIAID ChemDB information received cannot be sold and is only to be used for research purposes.(2R)-2-(3-fluoro-4-phenyl-phenyl)propanoic acidhttps://pubchem.ncbi.nlm.nih.gov/substance/?source=niaid&sourceid=166130
- NORMAN Suspect List ExchangeLICENSEData: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0https://creativecommons.org/licenses/by/4.0/Flurbiprofen | (-)-flurbiprofenNORMAN Suspect List Exchange Classificationhttps://www.norman-network.com/nds/SLE/
- Protein Data Bank in Europe (PDBe)
- RCSB Protein Data Bank (RCSB PDB)LICENSEData files contained in the PDB archive (ftp://ftp.wwpdb.org) are free of all copyright restrictions and made fully and freely available for both non-commercial and commercial use. Users of the data should attribute the original authors of that structural data.https://www.rcsb.org/pages/policies
- Springer Nature
- Thieme ChemistryLICENSEThe Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc-nd/4.0/
- Wikidatatarenflurbilhttps://www.wikidata.org/wiki/Q849769
- WikipediaTarenflurbilhttps://en.wikipedia.org/wiki/Tarenflurbil
- Medical Subject Headings (MeSH)LICENSEWorks produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.https://www.nlm.nih.gov/copyright.htmltarenflurbilhttps://id.nlm.nih.gov/mesh/M0542305.htmlAnti-Inflammatory Agents, Non-Steroidalhttps://id.nlm.nih.gov/mesh/M0001335.htmlGamma Secretase Inhibitors and Modulatorshttps://id.nlm.nih.gov/mesh/M000747845.htmlCyclooxygenase Inhibitorshttps://id.nlm.nih.gov/mesh/M0025664.html
- PubChemPFAS and Fluorinated Compounds in PubChemhttps://gitlab.com/uniluxembourg/lcsb/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf
- GHS Classification (UNECE)GHS Classificationhttps://unece.org/about-ghs
- MolGenieMolGenie Organic Chemistry Ontologyhttps://github.com/MolGenie/ontology/
- PATENTSCOPE (WIPO)SID 388974706https://pubchem.ncbi.nlm.nih.gov/substance/388974706
- NCBI
CONTENTS